Fig. 2.
Comparison of survival according to pathological complete response (pCR) in patients with HER2-postive breast cancer receiving neoadjuvant chemotherapy with and without Trastuzumab compared to patients with HER2-negative tumours 33.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.